AnaptysBio Inc. (ANAB) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for AnaptysBio Inc., updated every trading day.
Health Care · Biotechnology: Pharmaceutical Preparations
Price
$50.50
+1.75% today
Market cap
$1.5B
Overall quality
57/100
Kronos AI 30-day
+3.2%
8 of 8 simulated paths end higher
AnaptysBio Inc. (ANAB) is a Health Care company in Biotechnology: Pharmaceutical Preparations, worth $1.5B. It trades at $50.50, up 1.75% today, at 4.3 times earnings. Its overall quality score is 57 out of 100, ranked against the whole US market. 6 analysts' average target of $77.40 implies +53.3% from today's price. Kronos AI's 30-day forecast is +3.2% (8 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $77.40 |
| Low – high | $60.00 – $95.00 |
| Analysts | 6 |
| Upside to average | +53.3% |
Kronos AI 30-day forecast
| Expected close | $51.22 (+3.2%) |
| Likely range | +1.0% … +8.7% |
| As of | 2026-10-27 |
8 of 8 simulated paths end higher.
Quality scores
| Profitability | 62 |
| Solvency | 26 |
| Growth | 84 |
| Overall | 57 |
| P/E | 4.3 |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Pharmaceutical Preparations
For information only, not investment advice. Prices updated: 2026-10-29.